ZAP Surgical Systems, founded in 2014 and based in the United States, operates within the healthcare software and medical device sectors, focusing on innovative solutions for radiosurgery. The company has developed a self-shielding gyroscopic radiosurgery system, which represents a significant advancement in the treatment of various benign and malignant brain tumors. This technology allows for stereotactic radiosurgery without the need for traditional shielded radiation vaults, thereby enhancing safety and accessibility. A recent study published in March 2024 analyzed the outcomes of the first 100 patients treated with this system, demonstrating its application in clinical settings. The research highlights the importance of informed consent and regulatory approval in the deployment of new medical technologies. ZAP Surgical Systems employs between 51 to 200 individuals and reported revenue of approximately $13.4 million, indicating a growing presence in the healthcare technology landscape. The company is committed to advancing medical treatment options through research and development in radiosurgery techniques.